146 related articles for article (PubMed ID: 37529910)
1. Discovery of new thieno[2,3-
Sobh EA; Dahab MA; Elkaeed EB; Alsfouk AA; Ibrahim IM; Metwaly AM; Eissa IH
Future Med Chem; 2023 Jul; 15(13):1167-1184. PubMed ID: 37529910
[No Abstract] [Full Text] [Related]
2. Computer aided drug discovery (CADD) of a thieno[2,3-
Sobh EA; Dahab MA; Elkaeed EB; Alsfouk AA; Ibrahim IM; Metwaly AM; Eissa IH
J Biomol Struct Dyn; 2024 Mar; 42(5):2369-2391. PubMed ID: 37129193
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
4. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
5. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3-
Sobh EA; Dahab MA; Elkaeed EB; Alsfouk AA; Ibrahim IM; Metwaly AM; Eissa IH
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2220579. PubMed ID: 37288786
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
9. The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
Xia Z; Huang R; Zhou X; Chai Y; Chen H; Ma L; Yu Q; Li Y; Li W; He Y
Eur J Med Chem; 2021 Nov; 224():113711. PubMed ID: 34315040
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
11. Development of Novel Class of Phenylpyrazolo[3,4-
Aljohani AKB; El Zaloa WAZ; Alswah M; Seleem MA; Elsebaei MM; Bayoumi AH; El-Morsy AM; Almaghrabi M; Awaji AA; Hammad A; Alsulaimany M; Ahmed HEA
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834474
[TBL] [Abstract][Full Text] [Related]
12. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
El-Metwally SA; Abou-El-Regal MM; Eissa IH; Mehany ABM; Mahdy HA; Elkady H; Elwan A; Elkaeed EB
Bioorg Chem; 2021 Jul; 112():104947. PubMed ID: 33964580
[TBL] [Abstract][Full Text] [Related]
13. Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines.
Han C; Ren J; Su F; Hu X; Li M; Wang Z; Wu L
Anticancer Agents Med Chem; 2020; 20(6):724-733. PubMed ID: 32116203
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity.
Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA
Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3-d]pyrimidine derivatives as EGFR inhibitors.
Sayed MTM; Halim PA; El-Ansary AK; Hassan RA
Drug Dev Res; 2023 Sep; 84(6):1299-1319. PubMed ID: 37357422
[TBL] [Abstract][Full Text] [Related]
16. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new 1
Gaber AA; Sobhy M; Turky A; Abdulwahab HG; Al-Karmalawy AA; Elhendawy MA; Radwan MM; Elkaeed EB; Ibrahim IM; Elzahabi HSA; Eissa IH
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2283-2303. PubMed ID: 36000168
[TBL] [Abstract][Full Text] [Related]
18. New C2- and N3-Modified Thieno[2,3-d]Pyrimidine Conjugates with Cytotoxicity in the Nanomolar Range.
Mavrova AT; Dimov S; Yancheva D; Rangelov M; Wesselinova D; Naydenova E
Anticancer Agents Med Chem; 2022; 22(6):1201-1212. PubMed ID: 34315388
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
20. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
